在全球消化病学专家聚焦黏膜愈合指数的当下，伊曲莫德临床数据中最具突破性的发现当属其深度愈合指标。试验数据显示，接受治疗52周后患者内镜恢复正常比例达38.9%，较安慰剂组提升近3倍。这种针对肠道屏障功能的修复效果，源于S1P受体调节剂独特的双重作用机制：通过可逆性捕获淋巴细胞减少肠道炎症反应，同时激活上皮细胞S1PR1受体促进黏膜再生。相比传统抗TNF生物制剂仅阻断单一炎症因子，这种多靶点干预模式 ...

为探究 CXCR4 和 S1P?相互作用机制，首尔国立大学研究人员发现二者可形成异源二聚体，S1P/S1P?轴单向调节 CXCR4，为免疫细胞 ...

Researchers investigated the potential association between plasma apolipoprotein M (APOM) levels and the risk of adverse ...

为探究三阴性乳腺癌（TNBC）淋巴结转移机制，研究人员研究 MLPH 作用，发现其经特定轴抑制肿瘤进展，或为 TNBC 治疗提供新策略。 为了揭开 TNBC 淋巴结转移的神秘面纱，大连理工大学附属肿瘤医院（中国医科大学附属肿瘤医院、辽宁省肿瘤医院 & 研究所）等机构的研究人员踏上了探索之旅。他们的研究成果发表在《Journal of Translational Medicine》上，为 TNBC ...

Cenerimod is a novel oral S1P1 receptor modulator with potential to be a first- or best-in-class therapy for multiple autoimmune diseasesViatris previously acquired rights to cenerimod in all other ...

S.D. Standard Drilling PLC ( ($DE:S1P) ) just unveiled an update. S.D. Standard ETC Plc and Strategic Value Partners are exploring the sale of ...

All in all, the findings lay the foundation for the development of drugs that boost S1P to treat or prevent coronary artery ...

In its first phase 3 readout, oral S1P receptor modulator etrasimod met its objectives in patients with moderately-to-severely active ulcerative colitis, who had previously failed or were ...

Orally-active S1P agonist Zeposia (ozanimod) has been submitted to the FDA as a treatment for adults with moderately to severely active ulcerative colitis (UC), with a decision from the US ...